

Characteristics of Patients Undergoing Open Radical Cystectomy for Management of Muscle Invasive Bladder Cancer in A Tertiary Centre in Egypt

ABSTRACT

Aims: To represent the demographic and functional data of 47 patients with invasive bladder cancer managed with Open Radical Cystectomy (ORC) in the Urology Department of Tanta University Hospital between January 2019 and January 2021.

Study design: Retrospective cross-sectional study.

Place and Duration of Study: Urology Department, Tanta University Hospital, between January 2019 and January 2021.

Methodology: A retrospective analysis of a prospectively maintained data performed on the records of ORC for the period between January 2019 and January 2021.

Results: Most of the patients in were males (34 patients (72.3 %), with male to female ratio of 3:1. Most of the patients were either smokers or ex-smokers, while only 18 patients (38.3 %) never smoked before. Visible hematuria was the most common symptom at presentation (35 patients) 74.5 %. The main radiological imaging used for staging was CT Urography. Most of the tumors were urothelial in 66 % of patients. Squamous differentiation was the most common non urothelial variant with 8 patients. The presence of other non-urothelial variant histology was present in 6 patients.

Conclusion: This study revealed that in the tertiary hospital of Tanta University, the mean age of patients presented with bladder cancer and undergoing ORC, was 63.5 years. Visible haematuria was the most common complaint reported. The use of MRI is valuable in staging of locally advanced bladder cancer. Most of the tumours were urothelial with (66 %) with significant reduction in the incidence of squamous cell bladder cancer than the previously reported data. Neoadjuvant chemotherapy has become an integral part of the treatment protocol in cases of muscle invasive bladder cancer.

Keywords: [Radical, cystectomy, Bladder, cancer]

1. INTRODUCTION

Urothelial carcinoma of the bladder (UBC) is the most common urological malignancy in Egypt as it comes as the second most common cancer in males of all ages after liver cell cancer. In addition, it represents a staggering healthcare problem being the second most common urological cancer worldwide ^[1, 2].

Open radical cystectomy (ORC) remains the gold standard of care for patients with muscle invasive bladder cancer and for those with high-risk and recurrent non-muscle-invasive disease, providing efficacy regarding local control and long-term disease-free survival ^[3, 4]. However, ORC is associated with high perioperative complications, including significant intraoperative blood loss even when performed by the experienced surgeons ^[5]. Additionally, ORC involves longer incisions, prolonged abdominal wall retraction both leading to higher post-operative pain and increased wound complications. Exposure of the peritoneal surface during the procedure leads excessive fluid losses. Manual dissection in the boundaries of the narrow pelvis is challenging particularly in the retro vesical area ^[6, 7]. The results of radical cystectomy widely vary between different centres all over the world. Therefore, we represent the demographic and functional data of 47 patients with invasive bladder cancer managed with ORC in the Urology Department of Tanta University Hospital between January 2019 and January 2021.

2. MATERIAL AND METHODS

2.1 Study Design:

This is a cross sectional study with a retrospective analysis of a prospectively maintained data performed on the records of ORC for the period between January 2019 and January 2021.

2.2 Study Population:

The data of 47 patients was individually collected, tabulated, and analyzed.

2.3 Research Ethics:

This study was approved after the review by the Research Ethics Committee in Tanta University.

2.4 Outcome measurements:

Clinical variables included baseline patients' characteristics including age, body mass index (BMI), Charlton Comorbidity Index (CCI) ^[8] and full laboratory investigations were gathered. The WHO performance status was documented ^[9], and the American Society Association ASA score ^[10, 11]. Surgical Technique is a standard ORC performed by expert surgeons (MA, AH, MR) in Tanta University Hospital.

2.5 Statistics:

All statistical analysis was performed using SPSS version 26 software (IBM SPSS Statistics, IBM Corp., Armonk, NY).

3. RESULTS

3.1 Patients' characteristics:

Baseline demographic and functional data are summarized in (Table 1). Most of the patients in were males (34 patients (72.3 %), with male to female ratio of 3:1 in total of the study population. The mean age was 63.5 ± 6.68 years. The minimum age was 48 years, and the maximum age was 78 years. The majority of the patients were either smokers or ex-smokers, while only 18 patients (38.3 %) never smoked before. The mean BMI was 27.7 ± 5.5 kg/m². For standardization of the description of the patients' comorbidities and functional state, three widely acceptable measures were used.

Table (1): Patients' demographic data:

Demographic data	(n = 47)	
	No.	%
Sex		
Male	34	72.3
Female	13	27.7
Age (years)		
Min. – Max.	48.0 – 78.0	
Mean ± SD.	63.51 ± 6.68	
Median (IQR)	64.0 (60.0 – 69.0)	
Smoking status		
Non-smoker	18	38.3
Smoker	11	23.4
Ex-smoker	18	38.3
Height (m)		
Min. – Max.	1.56 – 1.96	
Mean ± SD.	1.72 ± 0.09	
Median (IQR)	1.73 (1.67 – 1.77)	
Weight (kgs)		
Min. – Max.	54.0 – 124.20	
Mean ± SD.	80.67 ± 13.56	
Median (IQR)	80.0 (72.15 – 89.60)	
BMI (kg/m ²)		
Min. – Max.	18.01 – 52.30	
Mean ± SD.	27.70 ± 5.55	
Median (IQR)	28.0 (24.67 – 29.72)	

ASA score		
1	13	27.7
2	23	48.9
3	11	23.4
Calculated charlson comorbidity index		
Min. – Max.	2.0 – 10.0	
Mean ± SD.	5.09 ± 1.79	
Median (IQR)	5.0 (4.0 – 6.0)	
Performance status		
0	39	83.0
1	8	17.0

3.2 Presentation and staging:

Visible hematuria was the most common symptom at presentation (35 patients) 74.5 %. This was followed by presence of significant lower urinary tract symptoms mainly storage type in the second order with (9 patients) 19.1%. Table 2 illustrates the common presentations among the included patients.

Table (2): The main complaints of the patients:

Main complaint	(n = 47)	
	No.	%
Visible (macroscopic) hematuria	35	74.5
Lower Urinary Tract Symptoms (LUTs)	9	19.1
Non-visible (microscopic) hematuria	2	4.3
Resistant UTI	1	2.1

The main radiological imaging used for staging was CT Urography. For more details about local disease progression or when there is a lack of clarity about clinical staging, MRI of the bladder and the pelvis was used in total of 8 patients. The use of PET CT was limited to only one patient with suspected metastatic disease due to abnormal LNs in imaging. Four patients had significant hydronephrosis in the imaging results (all unilateral) as shown in (Table 3).

Table (3): Different radiological imaging modalities used:

Modality Used	(n = 47)	
	No.	%
MRI	8	17.0
Presence of hydronephrosis in the imaging		
No	43	91.5
Unilateral	4	8.5
Bilateral	0	0.0
PET CT	1	2.12

All patients in both groups underwent a formal cystoscopic TURBT and the specimen was sent for histopathological examination. The results of the histopathology and the provisional clinical staging are demonstrated in (Table4). The results showed that most of the tumors were urothelial in 66 % of patients. Squamous differentiation was the most common non urothelial variant with 8 patients. The presence of other non-urothelial variant histology was present in 6 patients, one patient had undifferentiated carcinoma. The majority of the patients were cT2 (22 patients). Three patients (6.4%) were staged T3 (locally advanced disease). It was noted that all patients who were categorized with locally advanced disease, had non urothelial variants in their TURBT histology. One patient had suspicious pathologic lymph nodes in imaging.

Table (4): Clinical staging of the patients:

	(n = 47)	
	No.	%
Clinical T Stage		
Ta	4	8.5
Tis	1	2.1
T1	17	36.2
T2	22	46.8
T3	3	6.4
Histologic variants		

Urothelial	31	66.0
Squamous	8	17.0
Glandular	3	6.4
Sarcomatoid	3	6.4
Micropapillary	1	2.1
Undifferentiated	1	2.1
Clinical N Stage		
N0	46	97.9
Nx/N1	1	2.1
Clinical M Stage		
M0	47	100.0

Ten patients had a history of previous BCG intravesical therapy for either recurrent or HR-NMIBC. The presence of CIS in the TURBT histology was present in 28 patients. The presence of lymph-vascular invasion was detected in 5 patients. Nine patients were given neoadjuvant chemotherapy with the aim of local disease control and downstaging or due to non-urothelial variant histology (Table 5).

Table (5): Different preoperative parameters:

Pathological finding	(n = 47)	
	No.	%
Presence of Cis in TURBT histology		
No	19	40.4
Yes	28	59.6
Presence of LVI in TURBT histology		
No	42	89.4
Yes	5	10.6
Previous BCG intravesical therapy		

No	37	78.7
Yes	10	21.3
Neoadjuvant chemotherapy		
No	48	90.6
Yes	5	9.4

3.3 Preoperative variables:

Anemia that mandated preoperative blood transfusion for optimization of homeostasis was present in only one patient. Finally, the minimum hemoglobin blood level taken direct preoperatively was 9.3 gm/dl. Preoperatively, three patients received IV infusion of iron. The median creatinine level was 81 mmol/L (IQR 68 – 90) (Table 6).

Table (6): Different preoperative parameters:

preoperative parameters	(n = 47)	
	No.	%
Pre-operative blood transfusion		
No	46	97.9
Yes	1	2.1
Pre-operative iron transfusion		
No	44	93.6
Yes	3	6.4
E-GFR (ml/min/BSA)		
Min. – Max.	44.0 – 220.0	
Mean ± SD.	80.26 ± 25.63	
Median (IQR)	78.0(70.0 – 85.50)	
Creatinine (mmol/L)		
Min. – Max.	35.0 – 135.0	
Mean ± SD.	80.51 ± 17.44	
Median (IQR)	81.0(68.50 – 90.0)	

Hb	
Min. – Max.	9.30 – 15.80
Mean ± SD.	12.84 ± 1.77
Median (IQR)	12.80(11.35–14.45)

4. DISCUSSION

Open radical cystectomy is still the cornerstone treatment for muscle invasive bladder cancer disease and recommended by the guidelines in indicated cases of high risk non muscle invasive bladder cancer. This surgery has stood the test of time, however with multiple modifications and improvements aiming for decreasing the associated complications, enhancing the oncological outcomes and provision of better quality of life after surgery.

Most of the patients in both groups were males, with male to female ratio of 3:1. This is in concordance with the well documented ratio worldwide of three to fourfold higher incidence of BC in men than women ^[12, 13]. Numerous potential contributing factors may explain these demographic trends, including gender differences in exposures, metabolic enzyme activity, and disparities in the intensity of diagnostic evaluation ^[14, 15].

The mean age was 63.5 years. In an analysis of the incidence of bladder cancer in the Nile Delta region in Egypt, the average age of males (60.9 ±10.1 years) was similar to that of females 60.0 (±11.8 years) ^[16]. The younger age at presentation is also documented by the data from Kyritsi et al who found the mean age at diagnosis of bladder cancer in Egypt was the fifth decade of life ^[17].

Most of the patients were either current smokers or ex-smokers. These data may highlight the correlation between smoking and bladder cancer disease. An analysis conducted in 2011 on 467, 528 men and women demonstrated that former and active smokers had two- and fourfold increases, respectively, in bladder cancer risk relative to never smokers ^[18].

One study found that smoking was more strongly associated with the development of muscle invasive than with non-muscle invasive bladder cancer (NMIBC) ^[19]. While smoking cessation attenuates UCB risk, former smokers are still approximately twice as likely to develop the disease 20 years after quitting ^[20]. According to the currently available literature, smoking status and cumulative lifetime smoking exposure at diagnosis and at different times during treatment seem to affect disease recurrence, progression, and survival ^[21].

Visible hematuria was the most common symptom at presentation in the current study. This is in concordance with the data from the literature stating that hematuria either gross or microscopic is the most spotted presentation of bladder cancer ^[22-24].

The interest in MRI use comes from the limitations from the current imaging modalities in identifying metastatic disease and LN involvement preoperatively.

Approximately, 25% of patients having LN metastases are missed on current preoperative staging^[25].

To assess the role that MRI plays in the staging evaluation of a bladder lesion, there are a few clinical questions that need to be considered: How well does MRI differentiate \leq T1 bladder cancer from \geq T2 and what role can MRI play as a biomarker of aggressive disease? How well does MRI differentiate between T2 and \geq T3 disease? How can MRI enhance the detection of small, but malignant LN?^[26]

Green et al have found that contrast-enhanced MRI and diffusion weighted MR (DW-MRI) can confidently differentiate between non-muscle invasive bladder cancer and muscle invasive cancer with accuracy of more than 80%^[26]. MR imaging has been shown to allow more accurate staging of bladder carcinomas than CT because of its high soft-tissue contrast resolution, which allows clear differentiation between bladder wall layers^[27].

The limitations of traditional MR sequence are low sensitivity for identifying small lymph node metastases, and that it does not appear to be useful for staging per T-stage even with multiparametric MRI protocols^[26, 28]. Another disadvantage is that significant artifacts in bladder imaging include (lack of bladder distention, motion artifact, and chemical shift artifact) may limit the detection of small tumors and decrease sensitivity for plaque-like lesions^[29]. Another factors, the cost and the availability are to be considered specially in developing countries like Egypt.

In the current study, most of the tumors were urothelial in origin. These data demonstrate the shift of the histology of bladder cancer in Egypt. This is in concordance with previous research that reported a significant decline in incidence of SCC in Egypt, although the overall bladder cancer incidence has remained steady or even increasing due to a rise in TCC over the past 40 years^[30].

This is completely different from the reported data in 1980s where 22% of Egyptian BC cases were diagnosed with TCC while the majority of cases 78% were SCC^[16, 30]. By 2005, that ratio was nearly the opposite with 73% of bladder cancers diagnosed as TCC and 28% diagnosed as SCC^[16, 31]. A recent epidemiological study conducted in Tanta Urology department evaluating the characters of BC, the authors demonstrated that in 229 patients, 94% of the histopathological analysis reported TCC while SCC was present in only 5 % of the cases^[32].

The decrease in SCC cases has been explained by declining *S. haematobium* infection in the past 30 years due to construction of the Aswan Higher Dam in the 1960's, public health interventions for treatment, and changes in the Nile River system^[33].

In the current study, the presence of carcinoma in situ in both TURBT and final specimen histopathology was significantly reported. Kimura and colleagues evaluated the prognostic value of concomitant carcinoma in situ in the RC specimen^[34]. They have demonstrated that concomitant carcinoma in situ was reported in 39.4% of RC specimens, and it was not associated with overall mortality (pooled HR 0.92, 0.77-1.10), RFS (pooled HR 1.06, 0.99-1.13) or cancer specific mortality (pooled HR 1.00, 0.93-1.07)^[34].

The presence of lymph-vascular invasion (LVI) in TURBT and final specimen pathological report gained a lot of attention. Mari et al who conducted a systematic review and meta-analysis to investigate the effect of LVI in RC specimens on disease recurrence and CSM^[35]. They included 78,107 patients treated with RC. LVI was reported in 35.4% of the patients. They found that patients with LVI at RC had a 1.5-fold higher risk of developing

disease recurrence (pooled HR 1.57; 95% CI: 1.45–1.70) and to dying of their disease (pooled HR 1.59; 95% CI: 1.48–1.73) compared to patients without LVI, regardless of tumor stage, nodal status, or perioperative chemotherapy^[35].

Five patients were given neoadjuvant chemotherapy NAC. The selection for NAC is usually based on the clinical stage with more priority to locally advanced disease ($\geq T3$), presence of variant histology, multifocality of the tumor, the patients' co-morbidities, the baseline renal function, the delay time during diagnosis and importantly the patient preference^[36, 37]. The value of neoadjuvant chemotherapy has been demonstrated, Neoadjuvant cisplatin-containing combination chemotherapy (NAC) improves overall survival (OAS) (5-8% at five years), irrespective of the type of definitive treatment used^[38-41]. It is unclear if patients with variant histology will also benefit from NAC^[42]. A retrospective analysis demonstrated that patients with neuroendocrine tumors had improved OAS and lower rates of non-organ-confined disease when receiving NAC. In case of micropapillary differentiation, sarcomatoid differentiation and adenocarcinoma, lower rates of non-organ confined disease were found, but no statistically significant impact on OAS. Patients with SCC did not benefit from NAC^[43]. Currently, no tools are available to select patients who have a higher probability of benefitting from NAC. Response after two cycles of treatment is related to outcome^[42].

5. CONCLUSION

The mean age of bladder cancer was 63.5 years in this cohort of patients. Visible hematuria was the most common complaint reported. The use of MRI is valuable in staging of locally advanced bladder cancer. Most of the tumors were urothelial with (66 %) with significant reduction in the incidence of squamous cell bladder cancer than the previously reported data. The presence of carcinoma in situ and lymphovascular invasion in the TURBT histology may be valuable pathological predictors of recurrence that need to be thoroughly studied. Neoadjuvant chemotherapy has become an integral part of the treatment protocol in cases of muscle invasive bladder cancer.

COMPETING INTERESTS DISCLAIMER:

AUTHORS HAVE DECLARED THAT NO COMPETING INTERESTS EXIST. THE PRODUCTS USED FOR THIS RESEARCH ARE COMMONLY AND PREDOMINANTLY USE PRODUCTS IN OUR AREA OF RESEARCH AND COUNTRY. THERE IS ABSOLUTELY NO CONFLICT OF INTEREST BETWEEN THE AUTHORS AND PRODUCERS OF THE PRODUCTS BECAUSE WE DO NOT INTEND TO USE THESE PRODUCTS AS AN AVENUE FOR ANY LITIGATION BUT FOR THE ADVANCEMENT OF KNOWLEDGE. ALSO, THE RESEARCH WAS NOT FUNDED BY THE PRODUCING COMPANY RATHER IT WAS FUNDED BY PERSONAL EFFORTS OF THE AUTHORS.

REFERENCES

1. Siegel, R., D. Naishadham, and A. Jemal, *Cancer statistics, 2013*. CA: A Cancer Journal for Clinicians, 2013. **63**(1): p. 11-30.
2. Ibrahim, A.S., et al., *Cancer Incidence in Egypt: Results of the National Population-Based Cancer Registry Program*. Journal of Cancer Epidemiology, 2014. **2014**: p. 437971.

3. Parekh, D.J., et al., *Perioperative outcomes and oncologic efficacy from a pilot prospective randomized clinical trial of open versus robotic assisted radical cystectomy*. J Urol, 2013. **189**(2): p. 474-9.
4. Huang, G.J. and J.P. Stein, *Open radical cystectomy with lymphadenectomy remains the treatment of choice for invasive bladder cancer*. Curr Opin Urol, 2007. **17**(5): p. 369-75.
5. Bach, T., et al., *Laser Treatment of Benign Prostatic Obstruction: Basics and Physical Differences*. European Urology. **61**(2): p. 317-325.
6. Challacombe, B.J., et al., *The Role of Laparoscopic and Robotic Cystectomy in the Management of Muscle-Invasive Bladder Cancer With Special Emphasis on Cancer Control and Complications*. European Urology. **60**(4): p. 767-775.
7. Tan, W.S., B.W. Lamb, and J.D. Kelly, *Complications of Radical Cystectomy and Orthotopic Reconstruction*. Advances in Urology, 2015. **2015**: p. 7.
8. Charlson, M.E., et al., *A new method of classifying prognostic comorbidity in longitudinal studies: development and validation*. J Chronic Dis, 1987. **40**(5): p. 373-83.
9. Hinata, N., et al., *Performance status as a significant prognostic predictor in patients with urothelial carcinoma of the bladder who underwent radical cystectomy*. 2015. **22**(8): p. 742-746.
10. Saklad, M., M.D., *GRADING OF PATIENTS FOR SURGICAL PROCEDURES*. Anesthesiology: The Journal of the American Society of Anesthesiologists, 1941. **2**(3): p. 281-284.
11. Dripps, R.D., *New classification of physical status*. Anesthesiology, 1963. **24**: p. 111.
12. Siegel, R.L., K.D. Miller, and A. Jemal, *Cancer statistics, 2020*. 2020. **70**(1): p. 7-30.
13. Fajkovic, H., et al., *Impact of gender on bladder cancer incidence, staging, and prognosis*. World Journal of Urology, 2011. **29**(4): p. 457-463.
14. Dobruch, J., et al., *Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes*. European Urology, 2016. **69**(2): p. 300-310.
15. Zhang, Y., *Understanding the Gender Disparity in Bladder Cancer Risk: The Impact of Sex Hormones and Liver on Bladder Susceptibility to Carcinogens*. Journal of Environmental Science and Health, Part C, 2013. **31**(4): p. 287-304.
16. Fedewa, S.A., et al., *Incidence analyses of bladder cancer in the Nile delta region of Egypt*. Cancer epidemiology, 2009. **33**(3-4): p. 176-181.
17. Kyritsi, F., et al., *Urinary Bladder Cancer in Egypt: Are There Gender Differences in Its Histopathological Presentation?* Advances in Urology, 2018. **2018**: p. 3453808.
18. Freedman, N.D., et al., *Association Between Smoking and Risk of Bladder Cancer Among Men and Women*. JAMA, 2011. **306**(7): p. 737-745.

19. Jiang, X., et al., *Cigarette smoking and subtypes of bladder cancer*. 2012. **130**(4): p. 896-901.
20. Welty, C.J., et al., *Persistence of urothelial carcinoma of the bladder risk among former smokers: results from a contemporary, prospective cohort study*. *Urol Oncol*, 2014. **32**(1): p. 25.e21-5.
21. Rink, M., et al., *Smoking and Bladder Cancer: A Systematic Review of Risk and Outcomes*. *Eur Urol Focus*, 2015. **1**(1): p. 17-27.
22. Lenis, A.T., et al., *Bladder Cancer: A Review*. *JAMA*, 2020. **324**(19): p. 1980-1991.
23. Pashos, C.L., et al., *Bladder cancer: epidemiology, diagnosis, and management*. *Cancer Pract*, 2002. **10**(6): p. 311-22.
24. Babjuk, M., et al., *EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013*. *European Urology*, 2013. **64**(4): p. 639-653.
25. Svatek, R.S., et al., *Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort*. *BJU Int*, 2011. **107**(6): p. 898-904.
26. Green, D.A., et al., *Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques*. *BJU Int*, 2012. **110**(10): p. 1463-70.
27. Tekes, A., et al., *Dynamic MRI of bladder cancer: evaluation of staging accuracy*. *AJR Am J Roentgenol*, 2005. **184**(1): p. 121-7.
28. Cornelissen, S.W.E., et al., *Diagnostic Accuracy of Multiparametric MRI for Local Staging of Bladder Cancer: A Systematic Review and Meta-Analysis*. *Urology*, 2020. **145**: p. 22-29.
29. Barentsz, J.O., S.H. Ruijs, and S.P. Strijk, *The role of MR imaging in carcinoma of the urinary bladder*. *AJR Am J Roentgenol*, 1993. **160**(5): p. 937-47.
30. Felix, A.S., et al., *The changing patterns of bladder cancer in Egypt over the past 26 years*. *Cancer Causes Control*, 2008. **19**(4): p. 421-9.
31. Felix, A.S., et al., *The changing patterns of bladder cancer in Egypt over the past 26 years*. *Cancer Causes & Control*, 2008. **19**(4): p. 421-429.
32. Mohamed M. Elzoghby; Mohamed H. Radwan; Mohamed A. Elbendary, A.A.H., *Characters of the Bladder Cancer in Urology Department of Tanta University Hospitals*. *Nat Sci* 2020. **18**: p. 36-39.
33. El-Hawey, A.M., et al., *The epidemiology of schistosomiasis in Egypt: Gharbia Governorate*. *Am J Trop Med Hyg*, 2000. **62**(2 Suppl): p. 42-8.
34. Kimura, S., et al., *Prognostic Value of Concomitant Carcinoma In Situ in the Radical Cystectomy Specimen: A Systematic Review and Meta-Analysis*. 2019. **201**(1): p. 46-55.

35. Mari, A., et al., *A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancer*. Urol Oncol, 2018. **36**(6): p. 293-305.
36. Zamboni, S., et al., *How to improve patient selection for neoadjuvant chemotherapy in bladder cancer patients candidate for radical cystectomy and pelvic lymph node dissection*. World J Urol, 2020. **38**(5): p. 1229-1233.
37. Culp, S.H., et al., *Refining patient selection for neoadjuvant chemotherapy before radical cystectomy*. J Urol, 2014. **191**(1): p. 40-7.
38. Ghoneim, M.A., et al., *Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases*. J Urol, 1997. **158**(2): p. 393-9.
39. Stein, J.P. and D.G. Skinner, *Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure*. World J Urol, 2006. **24**(3): p. 296-304.
40. Calò, B., et al., *Neoadjuvant Chemotherapy Before Radical Cystectomy: Why We Must Adhere?* Curr Drug Targets, 2021. **22**(1): p. 14-21.
41. Advanced Bladder Cancer Meta-analysis, C., *Neo-adjuvant chemotherapy for invasive bladder cancer*. Cochrane Database of Systematic Reviews, 2004(1).
42. Witjes, J.A., et al., *EAU Guidelines on Muscle-invasive and metastatic Bladder Cancer 2020*, in *European Association of Urology Guidelines. 2020 Edition*. 2020, European Association of Urology Guidelines Office: Arnhem, The Netherlands.
43. Vetterlein, M.W., et al., *Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology*. Cancer, 2017. **123**(22): p. 4346-4355.